Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study

Trial Profile

Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Octreotate-Lu-177-DOTA-Tyr-3 (Primary) ; Capecitabine; Temozolomide
  • Indications Intestinal cancer; Neuroendocrine tumours; Pancreatic cancer
  • Focus Therapeutic Use
  • Acronyms CONTROL NETS
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Jun 2015 Planned initiation date changed from 1 Feb 2015 to 1 Jul 2015, according to ClinicalTrials.gov record.
    • 12 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top